藥明康德(02359.HK)第一季度淨利潤36.72億元 同比增長89.06%
格隆匯4月28日丨藥明康德(02359.HK)發佈公吿,公司2025年第一季度實現營業收入人民幣96.5億元,同比增長21.0%,其中持續經營業務收入93.9億元,同比增長23.1%。歸屬於上市公司股東的淨利潤36.72億元,同比增長89.06%;歸屬於上市公司股東的扣除非經常性損益的淨利潤23.3億元,同比增長14.50%;基本每股收益1.29元╱股。
截至2025年3月末,公司持續經營業務在手訂單人民幣523.3億元,同比增長47.1%。報吿期內來自美國客户收入人民幣63.8億元,同比增長28.4%;來自歐洲客户收入人民幣13.0億元,同比增長26.2%;來自中國客户收入人民幣15.3億元,同比下降1.3%;來自其他地區客户收入人民幣4.5億元,同比增長3.0%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.